Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2015-01-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with hemorrhagic stroke
All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
No intervention
No interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No interventions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with hemorrhagic stroke
* Anticipated length of stay in the neuroscience intensive care unit \> 48 hours
* Informed consent provided by the patient or by the patient's designated medical proxy
Exclusion Criteria
* Patients with pre-existing renal dysfunction (chronic kidney disease stages 3 - 5)
* Patients receiving renal replacement therapy
* Patients with an admission serum creatinine \> 1.4 mg/dL
* Patients with non-aneurysmal subarachnoid hemorrhage
* Patients with history of nephrectomy or body mass index \< 18 kg/m2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathryn A Morbitzer, PharmD
Role: PRINCIPAL_INVESTIGATOR
UNC Eshelman School of Pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina Hospitals
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-1491
Identifier Type: -
Identifier Source: org_study_id